Seven insiders at Latigo Biotherapeutics, Inc. (LTGO) collectively acquired approximately $17.64 million worth of company stock on August 10, 2026. The purchases were made at a price of $18.00 per share.
The transactions included significant buys from entities associated with Foresite, such as Capital Fund V, L.P., Capital Opportunity Fund V, L.P., Capital Management V, Llc, Capital Opportunity Management V, Llc, Capital Fund Vi Lp, and Capital Management Vi Llc. Additionally, James B. Tananbaum, identified as "Other," also made a substantial purchase.
This cluster buying activity, involving multiple insiders purchasing shares concurrently, is often interpreted as a strong positive signal regarding the company's future prospects within the biotechnology sector.